Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Phase 3
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1021
- Registration Number
- NCT01239732
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT01237496
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 597
- Registration Number
- NCT01235585
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 595
- Registration Number
- NCT01235520
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 71
- Registration Number
- NCT01235507
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 604
- Registration Number
- NCT01235559
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 301
- Registration Number
- NCT01234779
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 656
- Registration Number
- NCT01232569
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01230710
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Radiation therapyProcedure: Mesorectal excision
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-08-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01227707
© Copyright 2025. All Rights Reserved by MedPath